GM-CSF to treat Alzheimer’s disease
Dr. Huntington Potter and Dr. Timothy Boyd, have shown that subcutaneous Leukine administration significantly reduced brain amyloidosis and completely reversed cognitive impairment while increasing hippocampal synaptic area and microglial density in a mouse model of Alzheimer’s Disease (AD).
Amyloid deposits were shown to be reduced by more than 50 percent and memory deficits were completely reversed. The success of these translational studies, along with over two decades of accrued data on the safety of Leukine in the treatment of leukopenic patients, led to the initiation of clinical trials for use in AD in 2016. Interim results show statistically significant improvements and no drug-related adverse events such as micro-hemorrhage or vasogenic adema which have been observed in most other trials of anti-amyloid drugs.